Your browser doesn't support javascript.
loading
Basic Science Session 1. Biomarkers for Psoriatic Arthritis Treatment Response and Joint Damage Progression: An Update on 2 Industry-GRAPPA Projects.
Waddington, James C; Coleman, Orla; Mease, Philip J; Chandran, Vinod; O'Sullivan, Denis; FitzGerald, Oliver; Pennington, Stephen R.
Afiliación
  • Waddington JC; J.C. Waddington, MBiolSci, PhD, O. Coleman, PhD, Atturos Ltd., Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Coleman O; J.C. Waddington, MBiolSci, PhD, O. Coleman, PhD, Atturos Ltd., Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Mease PJ; P.J. Mease, MD, MACR, Rheumatology Research, Swedish Medical Center/Providence St. Joseph Health, Washington, and University of Washington School of Medicine, Seattle, Washington, USA.
  • Chandran V; V. Chandran, MBBS, MD, DM, PhD, Department of Medicine, Division of Rheumatology, University of Toronto, Toronto, and Krembil Research Institute, Toronto Western Hospital, Toronto, Ontario, Canada.
  • O'Sullivan D; D. O'Sullivan, BE, GRAPPA Patient Research Partner, Our Lady's Hospice & Care Services, Rheumatic & Musculoskeletal Disease Unit, Dublin, Ireland.
  • FitzGerald O; O. FitzGerald, MD, FRCPI, FRCP, Consultant Rheumatologist and Newman Clinical Research Professor, S.R. Pennington, PhD, School of Medicine, Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland.
  • Pennington SR; O. FitzGerald, MD, FRCPI, FRCP, Consultant Rheumatologist and Newman Clinical Research Professor, S.R. Pennington, PhD, School of Medicine, Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland. stephen.pennington@ucd.ie.
J Rheumatol ; 49(6 Suppl 1): 13-15, 2022 06.
Article en En | MEDLINE | ID: mdl-35365582
ABSTRACT
The Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA) has identified several priority areas for biomarker development, including biomarkers to predict at baseline which patients may progress to develop joint damage and whether a patient will respond to a specific targeted therapy. Two industry-GRAPPA projects were initiated in 2020 on these biomarker research areas (1) the Pfizer-GRAPPA project, focused on biomarkers of treatment response to tofacitinib in the Oral Psoriatic Arthritis TriaL program; and (2) the Lilly-GRAPPA project, focused on biomarkers of damage in the ixekizumab SPIRIT-P1 randomized controlled trial. Preliminary results from these 2 projects were presented by the GRAPPA team, with both studies showing promising initial results. Data from these studies will be published when the studies have been completed. Large-scale validation studies are required and are under discussion.
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Reumatología / Artritis Psoriásica Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Irlanda
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Psoriasis / Reumatología / Artritis Psoriásica Tipo de estudio: Clinical_trials / Diagnostic_studies / Prognostic_studies Límite: Humans Idioma: En Revista: J Rheumatol Año: 2022 Tipo del documento: Article País de afiliación: Irlanda